"10.1371_journal.pone.0052760","plos one","2012-12-28T00:00:00Z","Adam Schayowitz; Greg Bertenshaw; Emiko Jeffries; Timothy Schatz; James Cotton; Jessie Villanueva; Meenhard Herlyn; Clemens Krepler; Adina Vultur; Wei Xu; Gordon H Yu; Lynn Schuchter; Douglas P Clark","BioMarker Strategies, Baltimore, Maryland, United States of America; Melanoma Research Center, The Wistar Institute, Philadelphia, Pennsylvania, United States of America; Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America; Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, United States of America","Conceived and designed the experiments: DPC AS GB LS GHY MH JV. Performed the experiments: EJ TS JC. Analyzed the data: DPC AS GB EJ TS JC JV AV CK MH WX GHY LS. Contributed reagents/materials/analysis tools: AS GB EJ TS JC JV AV CK MH WX GHY LS. Wrote the paper: DPC.","Authors DPC, AS, GB, EJ, TS, JC are paid employees of BioMarker Strategies, each with equity stake in the private commercial company. DPC is a co-founder and a member of the Board of Directors of BioMarker Strategies. BioMarker Strategies manufactures the SnapPath platform, a research use only instrument. The Company is currently engaged in the patent prosecution of three applications (U.S. Serial #: 13/089,219; 12/258,251; and 12/125,790). Authors LS and WX have received research support from BioMarker Strategies. This does not alter the authors adherence to all the PLOS ONE policies on sharing data and materials.","2012","12","Adam Schayowitz","AS",13,TRUE,7,3,13,1,TRUE,TRUE,FALSE,0,NA,FALSE
